


CLAIMS

We claim:


1. A method of treating a neurological or psychiatric disease or disorder, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, in the evening or at night, or at about bedtime.


2. A method of treating a patient having a neurological or psychiatric disease or disorder, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, in the evening or at night, or at about bedtime.


3. A method of treating schizophrenia, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, in the evening or at night, or at about bedtime.

4. A method of treating a patient having schizophrenia, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, in the evening or at night, or at about bedtime.


5. The method of any one of claims 1-4, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered in the evening or at night.
6. The method of any one of claims 1-5, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered at about bedtime.
7. The method of any one of claims 1-6, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered at about the same time each day.
8. The method of any one of claims 1-7, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered once daily.
9. The method of any one of claims 1-8, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered orally.

10. The method of any one of claims 1-9, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a daily dose of from about 10 mg/day to about 100 mg/day.
11. The method of claim 10, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a daily dose of about 50 mg/day.
12. The method of claim 10, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered to the patient at a daily dose of about 75 mg/day.
13. The method of any one of claims 1-12, comprising administering Compound 1, or a pharmaceutically acceptable salt thereof, daily at a first dose, followed by administering Compound 1, or a pharmaceutically acceptable salt thereof, daily at a therapeutic dose.
14. The method of claim 13, wherein the first dose is about 50 mg/day.
15. The method of claim 13 or 14, wherein the therapeutic dose is about 25 mg/day, about 50 mg/day, about 75 mg/day or about 100 mg/day.
16. The method of any one of claims 13-15, wherein the first dose is administered daily for three days.
17. The method of any one of claims 13-16, further comprising administering Compound 1, or a pharmaceutically acceptable salt thereof, daily at a second dose, after administering Compound 1, or a pharmaceutically acceptable salt thereof, daily at a first dose and before administering Compound 1, or a pharmaceutically acceptable salt thereof, daily at a therapeutic dose.
18. The method of claim 17, wherein the second dose is administered daily for four days.
19. The method of claim 17 or 18, wherein the second dose is about 75 mg/day.
20. The method of any one of claims 1, 2 and 5-19, wherein the neurological or psychiatric disease or disorder is schizophrenia.
21. The method of any one of claims 1, 2 and 5-19, wherein the neurological or psychiatric disease or disorder is schizophrenia, cognitive impairment associated with schizophrenia,

schizophrenia spectrum disorder, schizophrenia negative symptoms, attenuated psychosis syndrome, prodromal schizophrenia, delusional disorder, psychosis, psychotic disorder, delirium, Tourette's syndrome, anxiety and related disorders including general anxiety disorder (GAD) and post-traumatic stress disorder, behavior disorder, affective disorder, depression, major depressive disorder, dysthymia, mood disorders including bipolar disorder, bipolar depression, treatment-resistant depression (TRD), and major depressive disorder (MDD); manic disorder, seasonal affective disorder, obsessive-compulsive disorder, narcolepsy, REM behavior disorder, substance abuse or dependency, Lesch-Nyhan disease, Wilson's disease, autism spectrum disorder, neurodegenerative disorders including dementia, dementia related psychosis (DRP), Parkinson's disease psychosis (PDP), and Alzheimer's disease agitation and psychosis, or Huntington's chorea.

22. The method of any one of claims 1, 2 and 5-19, wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, attenuated psychosis syndrome, prodromal schizophrenia, schizoid personality disorder, and schizotypal personality disorder.
23. The method of claim 21, wherein said psychosis is selected from organic psychosis, drug-induced psychosis, Parkinson's disease psychosis, and excitative psychosis.
24. The method of any preceding claim, wherein the hydrochloride salt of Compound 1 is administered to the patient.
25. The method of any preceding claim, wherein crystalline Form A of the hydrochloride salt of Compound 1 is administered to the patient.
26. The method of any preceding claim, wherein the method is effected without subjecting the patient to a clinically significant risk of adverse events.
27. The method of claim 26, wherein the adverse event is a patient's tendency for drug seeking behavior.
28. The method of any preceding claim, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for drug seeking behavior.


29. The method of any preceding claim, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for abuse, misuse, addiction, physical dependence, or tolerance.
30. The method of any preceding claim, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is not a controlled substance.
31. The method of any preceding claim, wherein a pharmaceutical composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, is not a controlled substance.
32. A method of treating a neurological or psychiatric disease or disorder, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for drug seeking behavior.


33. The method of claim 32, wherein the drug seeking behavior is abuse, misuse, addiction, physical dependence, or tolerance.
34. A method of treating a patient having a neurological or psychiatric disease or disorder, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for drug seeking behavior.


35. The method of claim 34, wherein the drug seeking behavior is abuse, misuse, addiction, physical dependence, or tolerance.
36. A method of treating schizophrenia, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for drug seeking behavior.

37. The method of claim 36, wherein the drug seeking behavior is abuse, misuse, addiction, physical dependence, or tolerance.
38. A method of treating a patient having schizophrenia, comprising administering to the patient a therapeutically effective amount of Compound 1



Compound 1,

or a pharmaceutically acceptable salt thereof, wherein administration of Compound 1, or a pharmaceutically acceptable salt thereof, does not clinically significantly increase the patient's tendency for drug seeking behavior.

39. The method of claim 38, wherein the drug seeking behavior is abuse, misuse, addiction, physical dependence, or tolerance.
40. The method of any one of claims 32-39, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is not a controlled substance.
41. The method of any one of claims 32-40, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered in the evening, at night, or at about bedtime.
42. The method of any one of claims 32-41, wherein the hydrochloride salt of Compound 1 is administered to the patient.
43. The method of any preceding claim, further comprising administering Compound 1, or a pharmaceutically acceptable salt thereof, in conjunction with one or more pharmaceutical agents.